Nils Wilking

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: MOLECULAR ONCOLOGY. 2023;17(6):925-945

Engaging European society at the forefront of cancer research and care: How discussions at the 5th Gago Conference on European Science policy led to the Heidelberg Manifesto.

Baumann M; Celis J; Ringborg U; Heitor M; Berns A; Albreht T; Arabadjiev J; Boutros M; Brandenburg M; Canhao H; Carneiro F; Chomienne C; De Lorenzo F; Eggermont AMM; Font A; Garralda E; Goulart M; Henrique R; Lawler M; Maier-Hein L; Meunier F; Oberst S; Oliveira P; Papatriantafyllou M; Schüz J; Solary E; Valencia A; Vargas R; Weiderpass E; Wilking N
Article: JOURNAL OF CANCER POLICY. 2022;34:100362

Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe.

Hofmarcher T; Lindgren P; Wilking N
Article: NATURE REVIEWS CLINICAL ONCOLOGY. 2022;19(3):207-215

The value of anticancer drugs - a regulatory view.

Pignatti F; Wilking U; Postmus D; Wilking N; Delgado J; Bergh J
Article: MOLECULAR ONCOLOGY. 2021;15(10):2507-2543

The Porto European Cancer Research Summit 2021.

Ringborg U; Berns A; Celis JE; Heitor M; Tabernero J; Schüz J; Baumann M; Henrique R; Aapro M; Basu P; Beets-Tan R; Besse B; Cardoso F; Carneiro F; van den Eede G; Eggermont A; Fröhling S; Galbraith S; Garralda E; Hanahan D; Hofmarcher T; Jönsson B; Kallioniemi O; Kásler M; Kondorosi E; Korbel J; Lacombe D; Carlos Machado J; Martin-Moreno JM; Meunier F; Nagy P; Nuciforo P; Oberst S; Oliveiera J; Papatriantafyllou M; Ricciardi W; Roediger A; Ryll B; Schilsky R; Scocca G; Seruca R; Soares M; Steindorf K; Valentini V; Voest E; Weiderpass E; Wilking N; Wren A; Zitvogel L
Article: JOURNAL OF CANCER POLICY. 2021;28:100279

Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets.

Rachev B; Wilking N; Kobelt G; Spandonaro F; Rajer M; Roediger A; Normand R; Zielinski C
Article: EUROPEAN JOURNAL OF CANCER. 2020;129:41-49

The cost of cancer in Europe 2018.

Hofmarcher T; Lindgren P; Wilking N; Jönsson B
Article: EUROPEAN JOURNAL OF CANCER. 2016;66:162-170

The cost and burden of cancer in the European Union 1995-2014.

Jönsson B; Hofmarcher T; Lindgren P; Wilking N
Article: EUROPEAN JOURNAL OF CANCER CARE. 2015;24(1):99-110

Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey.

Vrdoljak E; Torday L; Sella A; Leyman S; Bavbek S; Kharkevich G; Mardiak J; Szczylik C; Znaor A; Wilking N
Article: ACTA ONCOLOGICA. 2014;53(9):1197-1204

Audio-recorded information to patients considering participation in cancer clinical trials - a randomized study.

Bergenmar M; Johansson H; Wilking N; Hatschek T; Brandberg Y
Article: CHINESE CLINICAL ONCOLOGY. 2014;3(2):23

The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer.

Wilking N; Wilking U; Jönsson B
Article: BREAST. 2013;22(6):1142-1147

Angiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxel.

Linderholm BK; Lidbrink E; Tallroth E; Einbeigi Z; Svensson H; von Wachenfeldt A; Norberg B; Carlsson L; Olsson ME; Bergh J; Wilking N; Hatschek T
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(1):52-59

Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial.

Fahlén M; Fornander T; Johansson H; Johansson U; Rutqvist L-E; Wilking N; von Schoultz E
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2012;8(9):1360-1363

Cancer vaccines and immunotherapeutics: challenges for pricing, reimbursement and market access.

Jönsson B; Wilking N
Article: LAKARTIDNINGEN. 2010;107(40):2376-2377

[Great risk of future problems for Swedish cancer care].

Bergh J; Wilking N
Article: LAKARTIDNINGEN. 2010;107(16):1064

[Towards targeted treatment].

Wilking N
Article: EJHP PRACTICE. 2009;15(4):18-19

Access to cancer care is a key factor to progress in cancer treatment outcome

Jonsson B; Wilking N
Article: THORAX. 2008;63(10):866-871

Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study.

von Plessen C; Strand T-E; Wentzel-Larsen T; Omenaas E; Wilking N; Sundstrøm S; Sörenson S
Article: ANNALS OF ONCOLOGY. 2007;18:67-77

The effect of cancer drug vintage on cancer survival and mortality

Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:55-66

Market access for cancer drugs and the role of health economics

Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:49-54

Cancer research and development and the drug development process

Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:31-48

Market uptake of new oncology drugs

Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:23-30

Medical review

Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18:8-22

The burden and cost of cancer

Jonsson B; Wilking N
Article: ANNALS OF ONCOLOGY. 2007;18 Suppl 3:1

A global comparison regarding patient access to cancer drugs.

Jönsson B; Wilking N
Article: TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING. 2006;126(21):2828-2829

[Do Norwegian cancer patients receive the care they deserve?].

Wilking N; Jönsson B; Svedman C
Article: CLINICAL CANCER RESEARCH. 2006;12(14 Pt 1):4185-4191

Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.

Laakso M; Tanner M; Nilsson J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Bergh J; Isola J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2006;24(16):2428-2436

Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.

Scandinavian Breast Group Trial 9401; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
Article: EUROPEAN JOURNAL OF CANCER. 2000;36(8):976-982

High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

Kvinnsland S; Anker G; Dirix LY; Bonneterre J; Prove AM; Wilking N; Lobelle JP; Mariani O; di Salle E; Polli A; Massimini G
Article: JOURNAL OF CLINICAL ONCOLOGY. 1999;17(5):1413-1424

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.

Nabholtz JM; Senn HJ; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Molino A; Nortier JW; Richel DJ; Nagykalnai T; Siedlecki P; Wilking N; Genot JY; Hupperets PS; Pannuti F; Skarlos D; Tomiak EM; Murawsky M; Alakl M; Aapro M
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(10):1536-1545

Gastrointestinal Tract Cancer Liaison Office: an attempt to organise clinical research in Europe.

Bleiberg H; Gerard B; Wils J; Blijham G; Diaz-Rubio E; Herrmann R; Kerr D; Labianca R; Rougier P; Wilke HJ; Wilking N
Article: NEW ENGLAND JOURNAL OF MEDICINE. 1997;336(14):980-987

Improved survival with preoperative radiotherapy in resectable rectal cancer.

Swedish Rectal Cancer Trial; Cedermark B; Dahlberg M; Glimelius B; Påhlman L; Rutqvist LE; Wilking N
Article: BRITISH JOURNAL OF CANCER. 1996;74(3):479-481

A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor.

Smith I; Jones A; Spielmann M; Namer M; Green MD; Bonneterre J; Wander HE; Hatschek T; Wilking N; Zalcberg J; Spiers J; Seymour L
Article: BRITISH JOURNAL OF SURGERY. 1996;162(5):397-402

Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Swedish Rectal Cancer Trial.
Article: LAKARTIDNINGEN. 1995;92(9):849-853

[High-dose chemotherapy in breast cancer. Promising results in combination with stem cell support].

Ljungman P; Björkstrand B; Gahrton G; Nordenström J; Shanwell A; Glas U; Rotstein S; Rutqvist LE; Wilking N
Article: ONCOLOGY REPORTS. 1995;2(2):303-306

Differential-effects of fibroblast coculture on mcf-7 and mda-231 breast-carcinoma cell invasion through matrigel.

Popowicz P; Engel G; Wilking N; Linder S
Article: JOURNAL OF CLINICAL ONCOLOGY. 1995;13(2):430-434

Influence of prior and subsequent pregnancy on breast cancer prognosis.

von Schoultz E; Johansson H; Wilking N; Rutqvist LE
Article: LAKARTIDNINGEN. 1995;92(4):269-275

[The first breast cancer gene isolated. Safer risk assessment for affected families].

Iselius L; Larsson C; Lindblom A; Sandelin K; Wickman M; Wilking N
Visa fler

Alla övriga publikationer

Review: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2023;21(4):537-546

Review and Assessment of Policy Options for Improving Access to Combination Therapies in Oncology in Europe.

Henshall CH; Dankó D; Barham L; Espín J; Felix J; Harney M; Indra P; Mestre-Ferrandiz J; de Pouvourville G; Spandonaro F; Vončina L; Wilking N
Review: JOURNAL OF CANCER POLICY. 2021;28:100282

The European Code of Cancer Practice.

Lawler M; Oliver K; Gijssels S; Aapro M; Abolina A; Albreht T; Erdem S; Geissler J; Jassem J; Karjalainen S; La Vecchia C; Lievens Y; Meunier F; Morrissey M; Naredi P; Oberst S; Poortmans P; Price R; Sullivan R; Velikova G; Vrdoljak E; Wilking N; Yared W; Selby P
Review: BREAST. 2020;52:78-87

A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments.

Cardoso F; Wilking N; Bernardini R; Biganzoli L; Espin J; Miikkulainen K; Schuurman S; Spence D; Spitz S; Ujupan S; Zernik N; Gordon J
Review: ESMO OPEN. 2019;4(6):e000550

Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.

Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
Review: ESMO OPEN. 2016;1(6):e000127

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Lawler M; Banks I; Law K; Albreht T; Armand J-P; Barbacid M; Barzach M; Bergh J; Cameron D; Conte P; de Braud F; de Gramont A; De Lorenzo F; Diehl V; Diler S; Erdem S; Geissler J; Gore-Booth J; Henning G; Højgaard L; Horgan D; Jassem J; Johnson P; Kaasa S; Kapitein P; Karjalainen S; Kelly J; Kienesberger A; La Vecchia C; Lacombe D; Lindahl T; Löwenberg B; Luzzatto L; Malby R; Mastris K; Meunier F; Murphy M; Naredi P; Nurse P; Oliver K; Pearce J; Pelouchov J; Piccart M; Pinedo B; Spurrier-Bernard G; Sullivan R; Tabernero J; Van de Velde C; van Herk B; Vedsted P; Waldmann A; Weller D; Wilking N; Wilson R; Yared W; Zielinski C; Zur Hausen H; Le Chevalier T; Johnston P; Selby P
Review: SUPPORTIVE CARE IN CANCER. 2013;21(10):2925-2932

Clinical experience with Zarzio® in Europe: what have we learned?

Gascón P; Tesch H; Verpoort K; Rosati MS; Salesi N; Agrawal S; Wilking N; Barker H; Muenzberg M; Turner M
Review: ONCOLOGIST. 2013;18(3):248-256

A review of breast cancer care and outcomes in Latin America.

Justo N; Wilking N; Jönsson B; Luciani S; Cazap E
Review: LAKARTIDNINGEN. 2010;107(16):1075-1080

[Utilization of antineoplastic agents in Sweden and Europe].

Wilking N; Jönsson B; Björn W
Review: ANNALS OF ONCOLOGY. 2009;20(3):403-412

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.

McCabe C; Bergmann L; Bosanquet N; Ellis M; Enzmann H; von Euler M; Jönsson B; Kallen K-J; Newling D; Nüssler V; Paschen B; de Wilde R; Wilking N; Teale C; Zwierzina H; Biotherapy Development Association
Letter: ANNALS OF ONCOLOGY. 2007;18(9):1585-1587

Reply to 'Not credible:: a subversion of science by the pharmaceutical industry.: Commentary on A global comparison regarding patient access to cancer drugs

Jonsson B; Lichtenberg F; Wilking N
Editorial comment: ANNALS OF ONCOLOGY. 2007;18:2-7

A global comparison regarding patient access to cancer drugs -: Summary

Jonsson B; Wilking N
Letter: ACTA ONCOLOGICA. 1998;37(5):495-496

Treatment of rectal cancer.

Wilking N
Published conference paper: ANNALS OF SURGICAL ONCOLOGY. 1996;3(5):423-430

Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group.

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2023-2026
Forskningsspecialist, Onkologi-Patologi, Karolinska Institutet, 2023-2023

Artiklar

Alla övriga publikationer

Anställningar

Nyheter från KI

Kalenderhändelser från KI